- Home
- RYN vs PTGX Comparison
RYN vs PTGX Comparison
Compare RYN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- PTGX
- Stock Information
- Founded
- RYN 1926
- PTGX 2006
- Country
- RYN United States
- PTGX United States
- Employees
- RYN N/A
- PTGX N/A
- Industry
- RYN Real Estate Investment Trusts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- RYN Real Estate
- PTGX Health Care
- Exchange
- RYN Nasdaq
- PTGX Nasdaq
- Market Cap
- RYN 4.1B
- PTGX 3.7B
- IPO Year
- RYN N/A
- PTGX 2016
- Fundamental
- Price
- RYN $25.97
- PTGX $60.70
- Analyst Decision
- RYN Hold
- PTGX Strong Buy
- Analyst Count
- RYN 4
- PTGX 9
- Target Price
- RYN $28.00
- PTGX $70.44
- AVG Volume (30 Days)
- RYN 926.5K
- PTGX 906.1K
- Earning Date
- RYN 11-05-2025
- PTGX 11-06-2025
- Dividend Yield
- RYN 11.15%
- PTGX N/A
- EPS Growth
- RYN 389.17
- PTGX N/A
- EPS
- RYN 4.92
- PTGX 0.80
- Revenue
- RYN $1,239,943,000.00
- PTGX $209,180,000.00
- Revenue This Year
- RYN N/A
- PTGX N/A
- Revenue Next Year
- RYN $4.07
- PTGX $185.11
- P/E Ratio
- RYN $5.26
- PTGX $72.57
- Revenue Growth
- RYN 40.53
- PTGX N/A
- 52 Week Low
- RYN $21.84
- PTGX $33.31
- 52 Week High
- RYN $32.88
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- RYN 53.44
- PTGX 60.51
- Support Level
- RYN $26.02
- PTGX $57.90
- Resistance Level
- RYN $26.80
- PTGX $60.40
- Average True Range (ATR)
- RYN 0.38
- PTGX 2.51
- MACD
- RYN -1.53
- PTGX 0.02
- Stochastic Oscillator
- RYN 96.38
- PTGX 92.02
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.